Mesenchymal stromal cells for the treatment of Alzheimer's disease : Strategies and limitations
Copyright © 2022 Regmi, Liu, Shen, Kevadiya, Ganguly, Primavera, Chetty, Yarani and Thakor..
Alzheimer's disease (AD) is a major cause of age-related dementia and is characterized by progressive brain damage that gradually destroys memory and the ability to learn, which ultimately leads to the decline of a patient's ability to perform daily activities. Although some of the pharmacological treatments of AD are available for symptomatic relief, they are not able to limit the progression of AD and have several side effects. Mesenchymal stem/stromal cells (MSCs) could be a potential therapeutic option for treating AD due to their immunomodulatory, anti-inflammatory, regenerative, antioxidant, anti-apoptotic, and neuroprotective effects. MSCs not only secret neuroprotective and anti-inflammatory factors to promote the survival of neurons, but they also transfer functional mitochondria and miRNAs to boost their bioenergetic profile as well as improve microglial clearance of accumulated protein aggregates. This review focuses on different clinical and preclinical studies using MSC as a therapy for treating AD, their outcomes, limitations and the strategies to potentiate their clinical translation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in molecular neuroscience - 15(2022) vom: 21., Seite 1011225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Regmi, Shobha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer’s disease |
|---|
| Anmerkungen: |
Date Revised 25.10.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fnmol.2022.1011225 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347921027 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347921027 | ||
| 003 | DE-627 | ||
| 005 | 20231226034955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fnmol.2022.1011225 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347921027 | ||
| 035 | |a (NLM)36277497 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Regmi, Shobha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mesenchymal stromal cells for the treatment of Alzheimer's disease |b Strategies and limitations |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.10.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Regmi, Liu, Shen, Kevadiya, Ganguly, Primavera, Chetty, Yarani and Thakor. | ||
| 520 | |a Alzheimer's disease (AD) is a major cause of age-related dementia and is characterized by progressive brain damage that gradually destroys memory and the ability to learn, which ultimately leads to the decline of a patient's ability to perform daily activities. Although some of the pharmacological treatments of AD are available for symptomatic relief, they are not able to limit the progression of AD and have several side effects. Mesenchymal stem/stromal cells (MSCs) could be a potential therapeutic option for treating AD due to their immunomodulatory, anti-inflammatory, regenerative, antioxidant, anti-apoptotic, and neuroprotective effects. MSCs not only secret neuroprotective and anti-inflammatory factors to promote the survival of neurons, but they also transfer functional mitochondria and miRNAs to boost their bioenergetic profile as well as improve microglial clearance of accumulated protein aggregates. This review focuses on different clinical and preclinical studies using MSC as a therapy for treating AD, their outcomes, limitations and the strategies to potentiate their clinical translation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a mesenchymal stem cells | |
| 650 | 4 | |a mesenchymal stromal cells | |
| 650 | 4 | |a microglia | |
| 650 | 4 | |a neurons | |
| 650 | 4 | |a neuroprotection | |
| 700 | 1 | |a Liu, Daniel Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Kevadiya, Bhavesh D |e verfasserin |4 aut | |
| 700 | 1 | |a Ganguly, Abantika |e verfasserin |4 aut | |
| 700 | 1 | |a Primavera, Rosita |e verfasserin |4 aut | |
| 700 | 1 | |a Chetty, Shashank |e verfasserin |4 aut | |
| 700 | 1 | |a Yarani, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Thakor, Avnesh S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in molecular neuroscience |d 2008 |g 15(2022) vom: 21., Seite 1011225 |w (DE-627)NLM183921038 |x 1662-5099 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g day:21 |g pages:1011225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fnmol.2022.1011225 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |b 21 |h 1011225 | ||